Lycia Therapeutics Inc. (LYCA) vs Stoke Therapeutics, Inc. (STOK)

Lycia Therapeutics Inc. LYCA 30.50 +5.90%
Stoke Therapeutics, Inc. STOK 26.54 +1.80%

Lycia Therapeutics Inc. and Stoke Therapeutics, Inc. are both Biotechnology companies. Lycia Therapeutics Inc. and Stoke Therapeutics, Inc. are of similar size ($1.7B and $1.7B).

Metric	LYCA	STOK	Biotechnology median
P/E	—	n/m	10.60
P/S	—	64.12	9.40
P/B	—	5.13	2.13
Price to free cash flow	—	n/m	25.18
EV/EBITDA	—	n/m	0.66
EV/Sales	—	52.81	9.02
Earnings yield	—	(14.35%)	(32.88%)
Free cash flow yield	—	(11.93%)	(23.13%)

Metric	LYCA	STOK	Biotechnology median
Gross margin	—	100.00%	68.51%
Operating margin	—	(913.12%)	0.00%
Net margin	—	(862.07%)	0.00%
Free cash flow margin	—	(764.66%)	0.00%
Return on equity	—	(73.62%)	(51.96%)
Return on assets	—	(63.42%)	(46.06%)
Return on invested capital	—	(482.02%)	0.00%

Metric	LYCA	STOK	Biotechnology median
Revenue growth (TTM)	—	(86.28%)	6.76%
EPS growth (last fiscal year)	—	92.73%	29.88%
Revenue growth, 5-year CAGR	—	—	9.75%
Net income growth, 5-year CAGR	—	0.00%	0.00%

Metric	LYCA	STOK	Biotechnology median
Debt to equity	—	0.00	0.00
Current ratio	—	7.24	4.97
Net debt to EBITDA	—	14.29	1.01

Metric	LYCA	STOK	Biotechnology median
Dividend yield	—	—	0.41%
Payout ratio	—	—	—

Metric	LYCA	STOK	Biotechnology median
Market cap	1.66b	1.71b	161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack